This is the authors' abstract. We don't add key points for this paper.
Human DMD cDNA probes have been used to delineate possible deletions in 160 affected males. Approximately 56% of these individuals had detectable deletions, 29% of which mapped to a region centered around 500 kb from the 5' end of the gene whereas 69% mapped to a region located centrally 1,200 kb from the 5' end. We have observed no correlation between the extent of a deletion, its location, and clinical severity of the associated disease. For some cases with deletions in the two high-frequency deletion regions, the predicted effect upon translational reading frame of the resultant dystrophin mRNA did not correlate with the associated disease phenotype.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Baumbach et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: